Cell Surface Expression of the Bovine Leukemia Virus-Binding Receptor on B and T Lymphocytes Is Induced by Receptor Engagement

Madakasira Lavanya, Sandrina Kinet, Amélie Montel-Hagen, Cédric Mongellaz, Jean-Luc Battini, Marc Sitbon and Naomi Taylor

_J Immunol_ 2008; 181:891-898; doi: 10.4049/jimmunol.181.2.891

http://www.jimmunol.org/content/181/2/891
Cell Surface Expression of the Bovine Leukemia Virus-Binding Receptor on B and T Lymphocytes Is Induced by Receptor Engagement

Madakasira Lavanya, Sandrina Kinet, Amélie Montel-Hagen, Cédric Mongellaz, Jean-Luc Battini, Marc Sitbon, and Naomi Taylor

Bovine leukemia virus (BLV), one of the most common infectious viruses of cattle, is endemic in many herds. Approximately 30–40% of adult cows in the United States are infected by this oncogenic C-type retrovirus and 1–5% of animals will eventually develop a malignant lymphoma. BLV, like the human and simian T cell leukemia viruses, is a deltaretrovirus but, in contrast with the latter, the BLV receptor remains unidentified. In this study, we demonstrate that the amino-terminal 182 residues of the BLV envelope glycoprotein surface unit encompasses the receptor-binding domain. A bona fide interaction of this receptor-binding domain with the BLV receptor was demonstrated by specific interference with BLV, but not human T cell leukemia virus, envelope glycoprotein-mediated binding. We generated a rabbit Ig Fc-tagged BLV receptor-binding domain construct and ascertained that the ligand binds the BLV receptor on target cells from multiple species. Using this tool, we determined that the BLV-binding receptor is expressed on differentiating pro/pre-B cells in mouse bone marrow. However, the receptor was not detected on mature/quiescent B cells but was induced upon B cell activation. Activation of human B and T lymphocytes also induced surface BLV-receptor expression and required de novo protein synthesis. Receptor levels were down-regulated as activated lymphocytes returned to quiescence. In the human thymus, BLV-binding receptor expression was specifically detected on thymocytes responding to the IL-7 cytokine. Thus, expression of the BLV-binding receptor is a marker of enhanced metabolic activity in B cells, T cells, and thymocytes. The Journal of Immunology, 2008, 181: 891–898.

The bovine leukemia virus (BLV) is an oncogenic C-type retrovirus and is one of the most common infectious viruses of cattle, with a prevalence that is very heterogeneous worldwide. In some areas, the approximate infection rate in adult cows can reach 30–40%, as assessed by the presence of serum Abs. Approximately 30% of BLV-infected cattle develop a benign persistent lymphocytosis following infection, characterized by a polyclonal expansion of B cells generally expressing IgM and CD5 molecules at the cell surface (1–4). Under these conditions, the level of lymphocytosis is generally in the range of 20,000–80,000 lymphocytes/µL. After a prolonged incubation period, ~1–5% of infected cows will develop lymph node (LN) tumors. This malignant lymphoma, classified as “enzootic” or “endemic” bovine leukemia, is generally not detected before 6 years of age. Although cattle are the natural hosts of BLV, the virus can also induce B leukemia/lymphoma in sheep and goats following experimental transmission (reviewed in Refs. 4 and 5). The consequence is invariably fatal with lymphomatous involvement of multiple organs and death occurs within 3–6 mo of detection of leukemia or lymphoma. If the bone marrow (BM) becomes lymphomatous, animals present with lymphomas characterized by peripheral lymphocyte counts reaching 100,000/µL. The mechanisms via which the deregulated B cell homeostasis in infected animals evolves into a leukemia/lymphoma are not well understood. In experimentally infected sheep, deregulated B cell homeostasis results from an increased proliferation in the lymphatic system and increased cell death in the peripheral blood (6–9). Notably, other hematopoietic as well as nonhematopoietic cells can also be infected by BLV, including monocyte/macrophages, T-lineage cells, and endothelial cells (1, 10–14), but it is not clear whether they have a role in BLV-mediated pathogenesis since B cells have been shown to be the only targets of BLV infection in the peripheral blood (15).

BLV belongs to the deltaretrovirus genus that includes only a few other identified species: the human retroviruses human T cell leukemia virus (HTLV) types 1–4 and their known simian counterparts, simian T cell leukemia virus types 1–3. BLV and HTLV-1 are ~50% similar at the nucleotide level and share many common features in their molecular organization and disease pathogenesis. Accordingly, the gag and pol genes of HTLV-1 and BLV show strong homologies, indicative of their
BLV Env-BINDING RECEPTOR ON B AND T LYMPHOCYTES

FIGURE 1. Schematic representation of tagged BLV-truncated RBD. Schematic representation of the BLV envelope glycoprotein. The signal peptide (SP) and the extracellular (SU) and transmembrane (TM) components of BLV Env are represented as a modular organization based on that of HTLV Env (17). The amino-terminal 182 residues of BLV Env, encompassing the cleaved signal peptide (SP), the putative RBD in SU, with or without the PRR (wavy line), were fused to either a carboxy-terminal Fc domain of a rabbit IgG (BRBDrFc) or eGFP (BRBDeGFP), respectively.

BLV RBD Fc

BLV RBD eGFP

BLV Env

SU

TM

PRR

rFc

319

205

182

515

302

close evolutionary relationship (16). Deltaretroviruses, including BLV, share the same modular envelope organization as gammaretroviruses, even in the variable regions of the protein surface unit (SU) (17–19), oligomerizing as a trimer (20–22). Although the SU has been hypothesized to harbor the putative receptor-binding domain (RBD) (18, 23, 24), it is significant that the cellular receptor for BLV has yet to be identified. One reported candidate (25) was later shown to correspond to the δ subunit of the adapt-protein complex AP3, involved in intracellular transport rather than cell surface binding (26). Notably, the unidentified receptor appears to be expressed in many tissues and across many species (27).

We previously determined that the 183- and 178-amino-terminal residues of the HTLV-1 and -2 envelope glycoprotein (Env), respectively, are sufficient to efficiently bind target cells of different species (17, 19). This region of the SU, immediately upstream of the so-called proline-rich region (PRR), confers HTLV tropism to heterologous envelopes. Using a soluble-tagged construct encompassing this region (H₉₁₁), we were able to track HTLV receptor expression in lymphocyte subsets (25) and identified Glut1, the ubiquitous vertebrate glucose as a receptor for HTLV-1 and -2 Env (19, 29–31). It is of particular interest that Glut1, a deltaretrovirus receptor, like all other identified gammaretrovirus receptors, is a multimeric-spanning nutrient transporter (19, 24, 32).

Given the notable motif conservations and similar modular organizations of BLV and HTLV Env (Fig. 1), we hypothesized that the BLV Env region homologous to the amino-terminal 180 residues of HTLV Env would allow a bona fide interaction with the BLV receptor at the surface of target cells. In this study, we demonstrate that this fragment of the BLV SU encompasses the RBD. Interference assays demonstrated that an immunoadhesin, wherein the SU domain was fused to a rabbit IgG Fc (rFc) tag, was able to bind the BLV-binding receptor. Notably, the BLV RBD does not interact with the Glut1 HTLV receptor, demonstrating that these two closely related retroviruses use different cell receptors for entry, as suggested in an earlier study (33). Using our BLV RBD immunoadhesin, we were able, for the first time, to monitor the BLV-binding receptor on various cell types of different species. Moreover, we tracked binding receptor expression on primary hematopoietic cells and determined that expression of the BLV-binding receptor, undetectable on quiescent lymphocytes, is induced upon activation of B cells, T cells as well as thymocytes. Thus, in a manner analogous to the HTLV receptor, surface expression of the BLV-binding receptor on lymphocytes is up-regulated under conditions of enhanced metabolic activity.

Materials and Methods

Generation of soluble BLV envelope fusion proteins

The amino-terminal region of the BLV SU encoding 182 aa, comprising the 33-aa acid signal peptide, fused to a rFc at its carboxy-terminal was cloned into the pCIS expression vector. This vector contains a CMV promotor, followed by a SV40 intron upstream of the Env gene, and a SV40 poly(A) (34), and is referred to hereafter as pCIS-BLV RBD-FC. With the soluble protein referred to as BRBDrFc. A second BLV SU construct encoding the 212-amino-terminal amino acids includes the PRR and was generated with a carboxy-terminal enhanced GFP (eGFP) tag. This construct is referred to as pCSI-BLV RPRrGFP, with the soluble protein noted as BRBDeGFP. The BLV Env expression vector was derived from the pKCR3 vector (Invitrogen) in which the full-length Env gene (BLV strain strain D392) was introduced. This construct has an SV40 early promoter and the rabbit β-globin intron and poly(A). Cloning details are available upon request.

Recombinant proteins harboring the BLV RBD fused to rFc (BRBDrFc) or eGFP (BRBDeGFP) were produced by transfecting 293T cells with the appropriate constructs or with the empty control vector using the calcium phosphate method. After transfection, cells were washed twice with PBS and fresh DMEM was added. Medium containing the various soluble RBD proteins referred to as BRBDrFc or BRBDeGFP. A second BLV SU construct encompassing the cleaved off signal peptide (SP), the putative RBD in SU, of HTLV Env (17). The amino-terminal 182 residues of BLV Env, encompassing the cleaved signal peptide (SP), the putative RBD in SU, with or without the PRR (wavy line), were fused to either a carboxy-terminal Fc domain of a rabbit IgG (BRBDrFc) or eGFP (BRBDeGFP), respectively.

Generation of soluble BLV envelope fusion proteins

The amino-terminal region of the BLV SU encoding 182 aa, comprising the 33-aa acid signal peptide, fused to a rFc at its carboxy-terminal was cloned into the pCIS expression vector. This vector contains a CMV promotor, followed by a SV40 intron upstream of the Env gene, and a SV40 poly(A) (34), and is referred to hereafter as pCIS-BLV RBD-FC. With the soluble protein referred to as BRBDrFc. A second BLV SU construct encoding the 212-amino-terminal amino acids includes the PRR and was generated with a carboxy-terminal enhanced GFP (eGFP) tag. This construct is referred to as pCSI-BLV RPRrGFP, with the soluble protein noted as BRBDeGFP. The BLV Env expression vector was derived from the pKCR3 vector (Invitrogen) in which the full-length Env gene (BLV strain strain D392) was introduced. This construct has an SV40 early promoter and the rabbit β-globin intron and poly(A). Cloning details are available upon request.

Recombinant proteins harboring the BLV RBD fused to rFc (BRBDrFc) or eGFP (BRBDeGFP) were produced by transfecting 293T cells with the appropriate constructs or with the empty control vector using the calcium phosphate method. After transfection, cells were washed twice with PBS and fresh DMEM was added. Medium containing the various soluble RBD proteins referred to as BRBDrFc or BRBDeGFP. A second BLV SU construct encompassing the cleaved off signal peptide (SP), the putative RBD in SU, of HTLV Env (17). The amino-terminal 182 residues of BLV Env, encompassing the cleaved signal peptide (SP), the putative RBD in SU, with or without the PRR (wavy line), were fused to either a carboxy-terminal Fc domain of a rabbit IgG (BRBDrFc) or eGFP (BRBDeGFP), respectively.

Cell isolations and culture conditions

The JY EBV-transformed human B cell line, the Jurkat human T leukemic cell line, and the BL3 bovine lymphoblastoid cell line were grown in RPMI 1640 supplemented with 10% FCS. All other cell lines were grown in complete DMEM, including 293T human embryonic kidney cells, TE671 human medulloblastoma cells, HeLa human cervical carcinoma cells, NIH3T3 mouse fibroblast cells, COS-7 African green monkey kidney cells, PK15 porcine kidney cells, D17 canine osteosarcoma cells, A23 hamster fibroblast cells, CCL64 mink lung fibroblast cells, Mus dunni mouse tail fibroblast cells, TEK bovine embryonic thymus cells, KNS-R bovine nose mucosa cells, PO sheep kidney cells as well as the corresponding BLV-infected cell line, PO/BLV, and the BLV-infected fetal lamb kidney cell line FLK/BLV. TEK, KNS-R, PO, and PO/BLV cells were provided by R. Brie (Collection of Cell Lines in Veterinary Medicine, Insel Riems, Germany), BL3 and FLK/BLV were provided by L. Willens (Faculté Universitaire des Sciences Agronomiques de Gembloux, Gembloux, Belgium). The non-adherent S91 cell line was grown in serum-free Grace’s insect cell culture medium (Invitrogen). Twenty-four hours before their use in binding assays, cells were split and seeded at a confluence of 2 × 10⁵ cells in a 10-cm tissue culture plate.

Adult peripheral blood, obtained from healthy adult donors, as well as umbilical cord blood, obtained immediately after delivery of full-term infants, were collected in heparinized tubes. PBMC were separated from RBC upon Ficoll-Hypaque separation. CD⁴⁺ T cells were purified by negative selection using tetramer complexes in which one Ab recognizes a surface Ag on B cells, monocytes, NK cells, and CD⁸⁺ cells and the other recognizes glycoporphin A on the surface of RBC (RosetteSep; StemSep Technologies). Non-CD⁴⁺ T cells were then pelleted upon Ficoll-Hypaque separation. The percentage of contaminating CD³⁻ CD¹⁴⁺ monocytes was <0.5%. B cells were positively selected using a mixture of Abs that recognize the CD19 Ag present on mature and progenitors B cells (Easy Sep; StemSep Technologies). The purity of the selected cells was monitored after each isolation on a FACSCalibur (BD Pharmingen) following staining with either FITC-conjugated anti-CD3 and PE-conjugated anti-CD4 mAbs for T cells or a FITC-conjugated anti-CD19 mAb for B cells (Immunotech). The purity of the selected cells was >90%.

Human T and B lymphocytes were cultured in RPMI 1640 medium supplemented with 10% FCS, penicillin, and streptomycin. T cells were stimulated with immobilized anti-CD3 (OKT3) and anti-CD28 (clone 9.3; provided by C. June, University of Pennsylvania, Philadelphia, PA) mAbs (1 μg/ml) with the addition of rIL-2 (100 U/ml) at 48 h. Alternatively, cells were cultured in the presence of rIL-7 (10 ng/ml; generously provided by Cytheris). When indicated, cycloheximide was added to cell cultures at a concentration of 5 μg/ml (Sigma-Aldrich). B cells were stimulated using IgM and anti-IgM.
For analyses of murine B lymphocytes, cells were isolated from LN, spleen, and BM. For activation analyses, LN and spleen cells were resuspended at a concentration of 2.5 \times 10^6 cells/ml in RPMI 1640 supplemented with 10% FCS and 2-ME and activated with LPS at a concentration of 20 \mu g/ml.

Thymocytes were isolated from thymi removed during corrective cardiac surgery of infants in accordance with local ethics board regulations. Single-cell thymocyte suspensions were generated by physical disruption of tissue and filtration through 70- \mu m nylon screens. Thymocytes were then cultured in RPMI 1640 supplemented with 10% FCS in the presence or absence of IL-7 (10 ng/ml).

**Flow cytometry for Env binding and surface markers**

Before binding assays, adherent cells were detached with PBS containing 1 mM EDTA. Approximately, 3–5 \times 10^5 cells were centrifuged for 3–5 min at 600 \times g. Cells were resuspended in a 500-\mu l solution of either B_{RRBD}Fc, B_{RRBD}GFP, H_{RBBD}Fc, or control supernatants as indicated. Labeling was performed at 37°C for 30 min. After two washes in PBA buffer (PBS containing 2% FBS and 0.01% sodium azide), cells labeled with a rFc-linked fusion protein were incubated with a FITC-conjugated sheep anti-rFc Ab (1/500 dilution in PBA buffer; Sigma-Aldrich) for 20 min on ice. Cells were washed twice with PBA buffer and then analyzed on a FACScan, FACSCalibur, or FACSCanto (BD Biosciences).

**Interference and binding receptor expression assays**

One day prior to transfection, 293 T cells (5 \times 10^5) were plated in 6-well plates. Transfections of target cells with B_{RRBD}Fc and full-length BLV Env expression vectors (interference assay) or with the Glut1 expression vector (receptor expression) were performed using the calcium phosphate precipitation method. Cells were washed with DMEM 16 hours later and assayed for RBD binding by flow cytometry after an additional 24 h.

**Results**

**Generation of soluble BLV Env SU subdomains with BLV receptor-binding properties**

Based on the amino acid homology between HTLV and BLV Env, a putative BLV RBD encoding the amino-terminal 182 aa of the SU was tagged with rabbit Ig Fc sequences at the C-terminal end (B_{RRBD}Fc). A SU N-terminal BLV Env subdomain encompassing the PRR, encoding 212 residues, was also constructed as a fusion protein with rFc or eGFP coding sequences (B_{RRBD}GFP) (Fig. 1). The various constructs were transfected in 293T cells and the recombinant fusion proteins were secreted as assayed by immunoblotting with Abs directed against the C-terminal tags (data not shown).

To determine whether the truncated 212-aa and/or 182-aa BLV Env SU subdomains harbor BLV receptor-binding determinants, an Env-specific binding interference assay was performed. In this assay, 293T cells were transfected with the expression vector encoding B_{RRBD}Fc, without the PRR domain. Following transfection, binding of the soluble eGFP-tagged B_{RRBD}, harboring the PRR (residues 183–212), was monitored. Notably, B_{RRBD}GFP binding was significantly inhibited in B_{RRBD}Fc-transfected cells and this effect was specific as binding of a heterologous-related SU domain, the HTLV Env SU ligand (H_{RRBD}GFP), was not inhibited by transfection of the B_{RRBD}Fc-encoding plasmid (mean fluorescence intensity (MFI) of 14 vs 17 following transfection; Fig. 2A, top panel).

Similar interference results were also obtained after transfecting the entire BLV Env, with decreased B_{RRBD}GFP binding (MFIs diminishing from 95 to 27) under conditions where H_{RRBD}GFP binding was not affected (MFIs of 13 and 12, respectively; Fig. 2A, bottom panel). Thus, BLV Env interfered with B_{RRBD}GFP binding to levels that were equivalent to that of the B_{RRBD} subdomain. The ensemble of these data demonstrates that the 182-aa BLV Env SU subdomain, independent of the downstream PRR, is sufficient for specific cell surface binding to the BLV receptor.

**The HTLV and BLV envelopes bind to distinct receptor ligands**

As indicated in the introduction, the identified gammaretrovirus receptors are all multimembrane-spanning proteins. The homology and similar organization of the HTLV and BLV envelopes and their similar cell-type and species distribution made it important to test whether Glut1, the recently identified HTLV receptor, is recognized by the BLV envelope. As expected, transfection of 293T cells with a Glut1 expression vector resulted in a significantly increased level of binding to its HTLV Env SU ligand (H_{RRBD}Fc) (28, 31). Indeed, the MFI of H_{RRBD}Fc binding was ~10-fold higher in the Glut1-transfected population as compared with the untransfected cells (Fig. 2B).

Significantly though, binding to the
The BRBDrFc fusion protein was used to assess cell surface ex-
lines from different species
Env
The BLV
RBD does not interact with either endogenous or ectopic Glut1.
not detectable (Fig. 2C). Altogether, these data show that the BLV
NIH3T3). Expression was also monitored on the Sf9 insect cell line. Cells
of Glut1. As expected (29), the binding of HRBDrFc to human RBC
resulting in a preferential transport of the oxidized form of vitamin
B lymphocytes isolated from peripheral blood. Notably though,
expression (Fig. 3A), similar to that described for the related HTLV
receptor (24, 37, 38).
We further investigated BLV-binding receptor expression on
cell lines from species wherein BLV infection can result in B cell
leukemia/lymphoma, including cows, sheep, and goats. Indeed,
BRBDrFc binding was readily detected on bovine (TEK, KNS-R,
BL3) and ovine (PO) cell lines (Fig. 3B). Since it has been previ-
ously shown that these cell lines cannot be superinfected by the
virus (39), it was of interest to assess BLV-binding receptor ex-
pression on these cells. As shown in Fig. 3B, BBRBDrFc binding to
these cells was significantly lower than that detected on their non-
infected counterparts. These data strongly suggest that one me-
chanism negatively regulating BLV superinfection is related to re-
ceptor down-regulation and/or competition for binding site
occupancy. Finally, there was no detectable BRBDrFc binding to
the S9 insect cell line, demonstrating that the receptor is not ex-
pressed or not functional on invertebrate cells.

FIGURE 3. The BLV Env-binding receptor is expressed on diverse cell
lines of different species and is down-regulated upon BLV infection. A, BRBDrFc was used to assess the cell surface expression of the BLV-bind-
ing receptor on transformed cell lines derived from the following species: human (293T, TE671, HeLa, JY, and Jurkat), simian (COS-7), porcine
(PK15), dog (D17), hamster (A23), mink (CCL64), and mouse (Dunni and NIH3T3). Expression was also monitored on the S9 insect cell line. Cells
were incubated with the BRBDrFc for 30 min at 37°C, followed by incu-
bation with a FITC-conjugated anti-rabbit Fc Ab at 4°C. Binding was mon-
tored by flow cytometry. Filled histograms depict background binding in
the presence of the secondary FITC-conjugated anti-rabbit Ab alone while
specific binding is shown as a solid line. Data are representative of results
obtained in at least two independent experiments. B, BRBDrFc binding was
assessed on bovine (TEK, KNS-R, and BL3) and ovine (PO) cell lines (top
panels) as well as on the BLV-infected PO cell line and the fetal lamb
kidney cell line (FLK-BLV) (bottom panels).

The BLV Env-binding receptor is expressed on diverse cell
lines from different species
The BRBDrFc fusion protein was used to assess cell surface ex-
pansion of the BLV Env-BINDING RECEPTOR ON B AND T LYMPHOCYTES
position (Fig. 3A), similar to that described for the related HTLV
receptor (24, 37, 38).

Because there were previously no available tools to evaluate the
expression of the BLV receptor, its in vivo expression profile on
different target cells was not determined before this study. The data
presented in Fig. 3 indicate a ubiquitous expression on cell lines,
but expression on primary cell targets was not known. Given the B
lymphotropic nature of the virus, we first assessed BLV-binding
receptor expression on B-lineage cells. To determine whether there
is a differential expression on B lymphocytes during differentia-
tion, we analyzed murine BM cells because this compartment con-
tains pro-B, pre-B, and immature as well as mature B cells. The
various B cell subsets within the B220
+ population can be distin-
guished on the basis of several markers, including CD43 and IgM.
Indeed, staining with multiple sets of Abs along with BRBDrFc
demonstrated significantly higher levels of BLV-binding receptor
on the less differentiated pro-B and pre-B subsets as compared with
immature and mature B cells (Fig. 4A and data not shown).
Both pro- and pre-B cells, distinguished by CD25 and c-Kit ex-
pression, expressed the BLV-binding receptor (data not shown).
The ensemble of the experiments presented above demonstrated
that BLV receptor expression is modulated during B cell differ-
etiation in the BM, with the highest levels present on undiffer-
entiated B lymphocytes. Indeed, we were unable to detect BLV
receptor expression in mature murine B lymphocytes isolated from
spleen or LN and similarly could not detect the receptor in human
B lymphocytes isolated from peripheral blood. Notably though,
these mature lymphocytes are largely quiescent and all previously
identified gammaretrovirus receptors for which a function has been
assigned have been found to be transporters of various nutrients
and metabolites. We therefore hypothesized that expression of the
BLV Env-binding receptor would be sensitive to the metabolic
state of the cell. To test this hypothesis, we activated these cells ex
vivo via their Ag receptor and then assessed receptor levels. Sig-
ificantly, BLV Env-binding receptor levels were highly up-regu-
lated in all of these mature B cell populations following receptor
engagement (Fig. 4B).

The BLV-binding receptor is up-regulated at early time points
following TCR stimulation and its expression requires protein
synthesis
Like B cells, the vast majority of circulating T lymphocytes are
quiescent and are considered to have a very low metabolic activity,
with very low glucose uptake (31). As such, it was not surprising
to note that as in B cells, the BLV Env-binding receptor was not

BBL3) and ovine (PO) cell lines (Fig. 3
B
BLV Env-BINDING RECEPTOR ON B AND T LYMPHOCYTES

blymphocytes is
differentiation and activation dependent

Downloaded from http://www.jimmunol.org/ by guest on October 28, 2017
detected on quiescent human T lymphocytes. Notably though, activation of T cells via their Ag receptor (TCR) engagement using anti-CD3/anti-CD28 mAbs resulted in an induction of BRBDRFc binding in the three subsets is shown. B, BRBDRFc binding was assessed in freshly isolated (−) B220+ spleen and LN cells isolated from C57BL/6 mice as well as 48 h after LPS (20 μg/ml) stimulation (+). Human CD19+ lymphocytes were purified by positive selection and BRBDRFc binding was assessed before (−) and after (+) 3 days of BCR stimulation with an anti-IgM mAb (20 μg/ml).

Stimulation of quiescent T lymphocytes to enter into cycle and proliferate requires a 7- to 10-fold increase in protein synthesis (40). Indeed, translation is crucial for the propagation of TCR-induced signals since in its absence, activation is inhibited (41). To assess whether surface expression of the BLV-binding receptor required de novo protein synthesis, quiescent human T lymphocytes were stimulated with anti-CD3/anti-CD28 mAbs in the presence of the protein synthesis inhibitor, cycloheximide (CHX). The presence of CHX during 24 h did not significantly modulate the expression profile of the HTLV receptor Glut1 (29, 44) and indicate that the BLV-binding receptor is a novel cell cycle entry/proliferation marker in both B and T lymphocytes.

**FIGURE 4.** The BLV-binding receptor is expressed on differentiating B cells and is induced on mature B cell following receptor activation. A, Expression of the BLV-binding receptor on differentiating B cells was monitored in mouse BM. Pro-pre-B cells, immature B cells, and mature B cells were distinguished on the basis of IgM and B220 expression as shown and BBRD-Fc binding in the three subsets is shown. B, BBRD-Fc binding was assessed in freshly isolated (−) B220+ spleen and LN cells isolated from C57BL/6 mice as well as 48 h after LPS (20 μg/ml) stimulation (+). Human CD19+ lymphocytes were purified by positive selection and BBRD-Fc binding was assessed before (−) and after (+) 3 days of BCR stimulation with an anti-IgM mAb (20 μg/ml).

Surface BLV-binding receptor levels remain elevated for 24–144 h after TCR stimulation but then diminished significantly as T cells returned to a resting state (Fig. 5B). By day 11, T cells were quiescent and BBRD-Fc staining was undetectable (Fig. 5B). The BLV-binding receptor was also induced on umbilical cord T lymphocytes following their culture in the presence of the IL-7 cytokine (Fig. 4A), a T cell survival factor that can stimulate proliferation of these T cells without inducing an extensive activation profile (42, 43). These data are very reminiscent of the expression profile of the HTLV receptor Glut1 (29, 44) and indicate that the BLV Env-binding receptor is a novel cell cycle entry/proliferation marker in both B and T lymphocytes.

**FIGURE 5.** The BLV-binding receptor is an early marker of TCR stimulation and its expression requires protein synthesis. A, Human umbilical cord CD4+ T lymphocytes were purified by negative selection. Expression of CD69, CD25, and the BLV Env-binding receptor was assessed on freshly isolated cells (0 h) and after 2, 4, 6, 8, 16, and 24 h of TCR stimulation with immobilized anti-CD3 and anti-CD28 mAbs (solid line histograms). Expression of these markers at each time point was also evaluated in the presence of the protein synthesis inhibitor CHX (5 μg/ml; dashed histograms). Background fluorescence obtained with the secondary FITC-conjugated Ab alone is shown in each histogram (filled histograms). B, BLV Env-binding receptor expression was also assessed at extended time points after 3, 6, and 11 days of TCR stimulation as well as on T cells undergoing homeostatic proliferation induced by rIL-7 stimulation (10 ng/ml). Data are representative of results obtained in at least two independent experiments.

**IL-7-induced thymocyte blasts express high BLV Env-binding receptor levels**

Given the high potential of the BLV receptor to be a nutrient/metabolite transporter, we hypothesized that it would have a role in the proliferation and differentiation of lymphocytes. As such, it was of interest to study the expression profile of the BLV-binding receptor during T cell development, specifically assessing thymocytes. In freshly isolated human thymocytes, the BLV-binding receptor was detected on ~10–20% of cells, representing low percentages of immature CD4-D4-CD8+ (double negative (DN)), developing CD4+CD8+ (double positive (DP)), and a subset of single-positive (SP) CD4+ cells (Fig. 6). Upon stimulation of thymocytes with IL-7 (10 ng/ml), a subset of cells became blast like, as demonstrated by an increase in their forward and side scatters (Fig. 6). Analysis of these IL-7-induced thymocyte blasts revealed that the overwhelming majority, >90%, of these cells expressed the BLV-binding receptor as monitored by BBRD-Fc staining (Fig. 6). In marked contrast, the IL-7 nonresponsive DP thymocytes,
CD8 anti-CD8 mAbs. Histograms of BRBDrFc staining in the DN, DP, SP4, and SP8 populations within the indicated gates are presented. The relative expression of the BLV Env-binding receptor within each of these subsets was determined by incubation of thymocytes with B_RBD_Fc and secondary anti-rabbit IgG before staining with anti-CD4 and anti-CD8 mAbs. Histograms of B_RBD_Fc staining in the DN, DP, SP4, and SP8 populations are shown. Background staining obtained with the secondary FITC-conjugated Ab alone is depicted as filled histograms.

FIGURE 6. IL-7-responsive human thymocytes express high BLV Env-binding receptor levels. Expression of the BLV Env-binding receptor was assessed on human thymocytes immediately upon isolation or following a 5-day culture in the presence or absence of IL-7 (10 ng/ml) for 5 days. Following IL-7 stimulation, BLV Env-binding receptor expression was assessed on the non-blast and blast populations as determined by forward and side scatter profiles. The gates used for analyses of thymocyte subsets are shown. The distribution of DN, CD4+CD8+ DP, CD4+ SP (SP4) and CD8+ SP (SP8) thymocyte populations within the indicated gates is presented. The relative expression of the BLV Env-binding receptor within each of these subsets was determined by incubation of thymocytes with B_RBD_Fc and secondary anti-rabbit IgG before staining with anti-CD4 and anti-CD8 mAbs. Histograms of B_RBD_Fc staining in the DN, DP, SP4, and SP8 populations are shown. Background staining obtained with the secondary FITC-conjugated Ab alone is depicted as filled histograms.

Discussion
In this study, we report the generation of BLV SU subdomain constructs encompassing all sequences required for a specific interaction with the yet unidentified cellular BLV receptor. This amino-terminal SU subdomain fusion protein, harboring aa 1–182 of BLV Env, is efficiently expressed and secreted from eukaryotic cell lines in a functional, soluble form. Notably, we find that binding to the BLV receptor did not require the presence of immediately downstream PRR sequences of BLV Env. This is of particular importance since, in the context of HTLV, retroviral PRR or downstream sequences may bind to cell surface components other than the primary receptor (45, 46), and sequences outside the RBD in some gammaretrovirus SU appear to modulate or block binding and infection (47–49). Nevertheless, in the context of the BLV envelope, an Env-specific binding interference assay demonstrated that the BLV RBD alone decreased B_RBD binding to levels similar to that detected in the presence of the entire BLV Env.

Therefore, the tagged BLV RBD polypeptide described here provides a unique specific marker of the BLV-binding receptor. Using this ligand, we found that the BLV RBD was able to bind target cells of all mammalian species tested, consistent with previous reports that BLV can be experimentally transmitted to a 5-day culture in the presence or absence of rIL-7 (10 g/ml) for 5 days. Following IL-7 stimulation, BLV Env-binding receptor expression was assessed on the non-blast and blast populations as determined by forward and side scatter profiles. The gates used for analyses of thymocyte subsets are shown. The distribution of DN, CD4+CD8+ DP, CD4+ SP (SP4) and CD8+ SP (SP8) thymocyte populations within the indicated gates is presented. The relative expression of the BLV Env-binding receptor within each of these subsets was determined by incubation of thymocytes with B_RBD_Fc and secondary anti-rabbit IgG before staining with anti-CD4 and anti-CD8 mAbs. Histograms of B_RBD_Fc staining in the DN, DP, SP4, and SP8 populations are shown. Background staining obtained with the secondary FITC-conjugated Ab alone is depicted as filled histograms.

remained small with low forward and side scatters and <5% expressed the BLV-binding receptor (Fig. 6). The ensemble of these data reveals the BLV-binding receptor to be a remarkably specific marker of IL-7-responsiveness in developing thymocytes.

Moreover, we were able to assess the expression of the cellular BLV-binding receptor on primary target cells. Notably, BLV-binding receptor expression was detected on pro-B and pre-B cell subsets in murine BM but was present at lower levels on more differentiated B lymphocytes. We did not detect surface BLV-binding receptor expression on quiescent B or T lymphocytes but receptor levels were significantly induced following stimulation of the respective receptors. BLV-binding receptor expression was induced on both B and T lymphocytes under conditions of receptor as well as cytokine stimulation. This induction was independent of DNA synthesis because increased levels of BLV-binding receptor were detected as early as 4 h after receptor engagement while S phase entry requires at least 24 h of stimulation (28). Notably, BLV-binding receptor levels returned to undetectable levels at late time points following lymphocyte stimulation, consistent with their return to a quiescent state. We found that the surface expression of the BLV-binding receptor was dependent on de novo protein synthesis. This is likely due to the fact that resting B and T lymphocytes that make up the vast majority of the circulating lymphocyte pool are in a very low metabolic state. Although the persistent lymphocytosis and malignant lymphomas that can develop in BLV-infected animals are known to result from a deregulated B lymphocyte homeostasis, receptor levels on primary cells from these species have not yet been determined. We would predict that the pattern of receptor expression on bovine/ovine lymphocytes is similar to that which we observed here in murine and human lymphocytes, but it will be important to precisely evaluate this point. Moreover, receptor levels on bovine/ovine monocyte/macrophage and T-lineage cells should be evaluated since these cells have been shown to be infectable even if their role in pathogenesis is not known (1, 10–14). Elucidating the characteristics of receptor expression is crucial for furthering our understanding of BLV pathogenesis.

The characteristics of BLV expression on lymphocyte subsets are evocative of that previously reported for the HTLV receptor (28, 44). Indeed, even before this receptor was identified as the Glut1 glucose transporter, it had been determined that Glut1 expression is closely linked to the metabolic state of the lymphocyte (50–53). Significantly though, and as expected from previous studies of envelope interference, the BLV RBD did not interact with either ectopic or endogenous Glut1. Moreover, in contrast with the HTLV Env that binds extensively to human erythrocytes due to the extremely high levels of Glut1 on these cells, the BLV RBD did not interact with RBC. Thus, the cellular BLV-binding receptor is representative of a new metabolic marker that characterizes an activated lymphocyte. In addition to Glut1, the nutrient receptors that have been found to be crucial for lymphocyte development and proliferation include the CD71 transferrin receptor which mediates iron uptake (54–56) and CD98 (42F), a subunit of L-amino acid transporters (57–59). The identities of other nutrient receptors belonging to this group will undoubtedly be elucidated in the next few years and the BLV receptor promises to join this expanding list.

We recently determined that Glut1 expression in the human thymus characterizes a subset of thymocytes with high metabolic activity, as determined by their large size, cell cycle entry, and high glucose uptake (60). It appears that Glut1 expression is enhanced
on proliferating intermediate SP thymocytes and immature DP thymocytes that have recently undergone productive TCRβ gene rearrangements (60). In a situation analogous to that of Glu1, we determined that the BLV-binding receptor is expressed on only a minority of freshly isolated human thymocytes (10–20%), largely within the most immature DP thymocyte subset. IL-7, a cytokine that is crucial for thymocyte differentiation and proliferation, has previously been shown to induce responses in immature DN and mature SP cells, but not DP cells (61–63). In agreement with these data, we find that those IL-7-responsive human thymocytes, monitored as a function of their size and blast formation, are in vast majority DP and DN cells, excluding the DP population. It is therefore notable that >90% of these IL-7-responsive thymocytes express the BLV-binding receptor as compared with <5% of the nonresponsive population. Thus, IL-7 responsiveness thymocytes are specifically characterized by their expression of the cellular BLV-binding receptor.

All identified gammaretrovirus receptors are multimembrane-spanning protein members whose function, when identified, has consistently been that of a facilitative nutrient or metabolite transporter. As such, this is highly likely to be a defining characteristic of the cellular BLV receptor. Importantly, the ensemble of the results reported here demonstrates that the BLV-binding receptor is a novel marker of B and T lymphocyte activation, closely linked to the metabolic state of the cell. Our generation of a BLV SU ligand reagent that binds to target cells from multiple species has significant potential; it can be used to assess the metabolic state of lymphocytes from a wide range of mammals, an especially important feature in species where Abs to lymphocyte activation markers have not been produced. Moreover, our data now provide important clues as to the nature of the BLV-binding receptor and the mechanisms via which this virus can be transmitted to an uninfected lymphocyte. The data presented here lay the groundwork for studies aimed at furthering our understanding of the natural as well as experimental transmission of BLV infection and elucidating the characteristics of the lymphocyte subsets that can potentially be infected in vivo.

Acknowledgments

We thank R. Mamoun for the gift of BLV plasmids, Roland Riebe (CCLV), Jean Claude Twizere and Luc Willems (FSAGX) for the gift of cell lines. We are extremely grateful to P. Merida and S. Mnechen for expert assistance. L. Swainson, H. Abe, and J. Touhami generously provided support and we thank all members of our laboratory for insightful discussions.

Disclosures

The authors have no financial conflict of interest.

References


